Neoadjuvant chemotherapy (NACT) is employed in patients with breast cancer (BC) with the aim of reducing tumor burden and improving surgical outcomes. We evaluated the levels of energy metabolites pre- and post-radiotherapy (RT) in breast cancer (BC) patients who previously received NACT and investigated the alterations of these metabolites in relation to the patient achieving a pathologic complete response to NACT.
Materials and methods
We included 37 BC patients who were treated with NACT following surgery and analyzed the concentrations of energy balance-related metabolites using targeted metabolomics before and one month after the end of RT. The control group was composed of 44 healthy women.
Pre-radiotherapy, patients had significant decreases in the plasma levels of 12 metabolites. RT corrected these alterations and the improvement was superior in patients with a pathologic complete response.
Our results highlight the importance of metabolism in the outcomes of patients with BC.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Early Breast Cancer Trialists Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mor tality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.
Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600–8.
Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.
Castaneda SA, Strasser J. Updates in the treatment of breast cancer with radiotherapy. Surg Oncol Clin N Am. 2017;26:371–82.
Aristei C, Kaidar-Person O, Arenas M, et al. The 2016 assisi think tank meeting on breast cancer: white paper. Breast Cancer Res Treat. 2016;160:211–21.
Arenas M, Montero Á, de Las Peñas MD, et al. The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement. Clin Transl Oncol. 2016;18:582–91.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
Arenas M, Rodríguez E, García-Heredia A, et al. Metabolite normalization with local radiotherapy following breast tumor resection. PLoS ONE. 2018;13:e0207474.
Sloan JA, Loprinzi CL, Laurine JA, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001;19:3539–46.
Bayo E, Herruzo I, Arenas M, et al. Consensus on the regional lymph nodes irradiation in breast cancer. Clin Transl Oncol. 2013;15:766–73.
Algara M, Arenas M, De Bayo DLPE, et al. Radiation techniques used in patients with breast cancer: results of a survey in Spain. Rep Pract Oncol Radiother. 2012;17:122–8.
Fort-Gallifa I, García-Heredia A, Hernández-Aguilera A, et al. Biochemical indices of oxidative stress and inflammation in the evaluation of peripheral artery disease. Free Radic Biol Med. 2016;97:568–76.
Riera-Borrull M, Rodríguez-Gallego E, Hernández-Aguilera A, et al. Exploring the process of energy generation in pathophysiology by targeted metabolomics: performance of a simple and quantitative method. J Am Soc Mass Spectrom. 2016;27:168–77.
Grootveld M. Introduction to the applications of chemometric techniques in ‘Omics’ research: Common pitfalls, misconceptions and ‘rights and wrongs’. In: Grootveld M, editor. Metabolic profiling: disease and xenobiotics. Cambridge: Royal Society of Chemistry; 2014. p. 1–34.
Chai Y, Wang J, Wang T, et al. Application of 1H NMR spectroscopy-based metabolomics to feces of cervical cancer patients with radiation-induced acute intestinal symptoms. Radiother Oncol. 2015;117:294–301.
Mörén L, Wibom C, Bergström P, Johansson M, Antti H, Bergenheim A. Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas. Radiat Oncol. 2016;11:51.
Xiao X, Hu M, Zhang X, Hu JZ. NMR-based metabolomics analysis of liver from C57BL/6 mouse exposed to ionizing radiation. Radiat Res. 2017;188:44–55.
Laiakis EC, Strawn SJ, Brenner DJ, Fornace AJ Jr. Assessment of saliva as a potential biofluid for biodosimetry: a pilot metabolomics study in mice. Radiat Res. 2016;186:92–7.
Baldini N, De Milito A, Feron O, et al. Annual Meeting of the International Society of Cancer Metabolism (ISCaM): metabolic networks in cancer. Front Pharmacol. 2017;8:411.
Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Novel targeted therapies for cancer cachexia. Biochem J. 2017;474:2663–788.
Long JP, Li XN, Zhang F. Targeting metabolism in breast cancer: how far we can go? World J Clin Oncol. 2016;7:122–30.
Cao MD, Lamichhane S, Lundgren S, et al. Metabolic characterization of triple negative breast cancer. BMC Cancer. 2014;14:941.
Luo J, Zhou Z, Yang Z, et al. The value of 18F-FDG PET/CT imaging combined with pretherapeutic Ki67 for early prediction of pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer. Medicine (Baltimore). 2016;95:e2914.
Groheux D, Biard L, Giacchetti S, et al. 18F-FDG PET/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: Influence of the chemotherapy regimen. J Nucl Med. 2016;57:536–43.
Kostakoglu L, Duan F, Idowu MO, et al. A phase II study of 3'-deoxy-3'-18F-fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688. J Nucl Med. 2015;56:1681–9.
This study was funded, in part, by a grant from Associació Oncològica Dr. Amadeu Pelegrí (AODAP/2015; Salou, Spain). The authors thank the members of this Association together with all the volunteers from Salou and the surrounding areas for their enthusiastic support for our research.
Conflicts of interest
The authors declare that they have no conflicts of interest.
The study was approved by the Ethics Committee (Institutional Review Board) of the Hospital Universitari de Sant Joan de Reus (project code: CEIM 014/2017).
All patients signed a written informed consent according to the declaration of Helsinki.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Arenas, M., Fernández-Arroyo, S., Rodríguez-Tomàs, E. et al. Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy. Clin Transl Oncol 22, 1078–1085 (2020). https://doi.org/10.1007/s12094-019-02232-6
- Breast cancer
- Energy metabolism
- Neoadjuvant chemotherapy